Full list of people entitled to free NHS prescriptions as freeze extended from April
Prescription charges have been frozen at £9.90 but some people may be able to cut this down to…
All about new ‘triple-G’ drug that’s helped patients lose a quarter of their body weight
G whiz! The latest experimental GLP-1 from Eli Lilly isn’t just a diabetes drug — it also facilitates weight…
Large GLP-1 Drug Review Takes Closer Look at Risks, Rewards
Moderate- to high-quality evidence from an umbrella review on non-cardiometabolic outcomes reinforced links between GLP-1 therapies and risks…
Free Market Ozempic Will Make a Huge Difference to Tens of Millions of People
Photo by David Trinks The New York Times had an interesting piece on the implications of Ozempic becoming…
How GLP-1 weight loss drugs are shaping the future of European food demand
Economists at ING have released a new report on the expected impact appetite-suppressing weight loss medications will have…
New Wegovy subscription program could save patients $1,200 a year – NBC 5 Dallas-Fort Worth
The maker of the GLP-1 weight-loss drug Wegovy is promising “a lower, predictable monthly price” for patients who…
Yes, GLP-1s Are Changing What Food People Buy — Here’s How
GLP-1 medications like Ozempic and Wegovy have surged in use over the last five years for their role…
FDA Approves Eli Lilly’s GLP-1 Pill
The US Food and Drug Administration on Wednesday approved a new obesity pill called Foundayo. Taken once daily,…
List of Medications That Could Disqualify You From Driving
Following news that Tiger Woods was carrying two hydrocodone pills—which are commonly prescribed for pain—when he was interviewed…
FDA approves GLP-1 weight loss pill Foundayo from Eli Lilly
The Food and Drug Administration on Wednesday approved a new weight loss pill from drugmaker Eli Lilly. Subscribe…
Digant Sharma and Vibha Jain Launch Hypnotherapy Private Limited
SMPL Mumbai (Maharashtra) [India], April 1: In a significant development for India’s mental wellness and holistic healing landscape,…
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data
– PGN-EDODM1 was generally well-tolerated with all adverse events mild or moderate and no serious adverse events reported…